These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12737526)

  • 1. Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.
    Lemere CA; Spooner ET; Leverone JF; Mori C; Iglesias M; Bloom JK; Seabrook TJ
    Neurochem Res; 2003 Jul; 28(7):1017-27. PubMed ID: 12737526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: will vaccination work?
    Dodart JC; Bales KR; Paul SM
    Trends Mol Med; 2003 Mar; 9(3):85-7. PubMed ID: 12657428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
    Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ
    Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.
    Schiltz JG; Salzer U; Mohajeri MH; Franke D; Heinrich J; Pavlovic J; Wollmer MA; Nitsch RM; Moelling K
    J Mol Med (Berl); 2004 Oct; 82(10):706-14. PubMed ID: 15241501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current concepts and future prospects for Alzheimer disease vaccines.
    Heppner FL; Gandy S; McLaurin J
    Alzheimer Dis Assoc Disord; 2004; 18(1):38-43. PubMed ID: 15195462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.
    Maier M; Seabrook TJ; Lemere CA
    Neurodegener Dis; 2005; 2(5):267-72. PubMed ID: 16909008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
    Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA
    Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.
    Nikolic WV; Bai Y; Obregon D; Hou H; Mori T; Zeng J; Ehrhart J; Shytle RD; Giunta B; Morgan D; Town T; Tan J
    Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2507-12. PubMed ID: 17264212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.
    Holtzman DM; Bales KR; Paul SM; DeMattos RB
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1603-13. PubMed ID: 12453677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards Alzheimer's disease vaccination.
    Solomon B
    Mini Rev Med Chem; 2002 Feb; 2(1):85-92. PubMed ID: 12369959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
    Wilcock DM; Colton CA
    J Alzheimers Dis; 2008 Dec; 15(4):555-69. PubMed ID: 19096156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
    Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
    J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Res; 2017 Jun; 119():7-14. PubMed ID: 28111220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine development for Alzheimer's disease.
    Dasilva KA; Aubert I; McLaurin J
    Curr Pharm Des; 2006; 12(33):4283-93. PubMed ID: 17105428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
    Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
    Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.
    Monsonego A; Maron R; Zota V; Selkoe DJ; Weiner HL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10273-8. PubMed ID: 11517335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.